Navigation Links
Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2011 Second Quarter Earnings Conference Call on Tuesday, February 15, 2011 at 8:30 a.m. E.T.
Date:2/8/2011

CHENGDU, China, Feb. 8, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a pharmaceutical company that develops, manufactures and markets patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, today announced that the senior management will host a conference call to discuss its fiscal year 2011 second quarter financial results at 8:30 a.m. E.T. on Tuesday, February 15, 2011.

Interested parties may access the call by dialing 1-877-941-1427 (toll free) or 1-480-629-9664 (international).

The conference ID is 4410581. It is advisable to dial in approximately 5-10 minutes prior to the start of the call.

A replay will be available from February 15, 2011 till March, 1, 2011 and can be accessed by dialing 1-877-870-5176 (toll free) or 1-858-384-5517 (international). The passcode is 4410581.

This call will be webcast by ViaVid Broadcasting and can be accessed at the following link:

http://viavid.net/dce.aspx?sid=0000817C

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc. (TPI), headquartered at Chengdu, China, specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures and markets a comprehensive portfolio of 56 products, of which 23 are listed in the highly selective National Reimbursement List, 7 are included in the Essential Drug List of China. TPI has a pipeline of 10 products pending SFDA approval targeting high incidence indications such as cardiovascular disorders. TPI has an extensive nationwide distribution network with 730 sales representatives out of totaled 1,365 employees. For more information about TPI, please visit http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval process, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerBoard DirectorTianyin Pharmaceutical Co., Inc.Web:   http://www.tianyinpharma.com Email: Dr.Tong@tianyinpharma.com Tel:   +86-28-8551-6696 (Chengdu, China)+86 134 36 550011 (China)+1-949-350-6999 (U.S.)Address:23rd Floor Unionsun Yangkuo PlazaNo. 2, Block 3, South Renmin RoadChengdu, 610041China
'/>"/>

SOURCE TPI
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Pharmaceutical to Hold 2010 Shareholder Annual Meeting on March 21, 2011 at NYSE
2. Tianyin Reports Record First Quarter Fiscal Year 2011 Financial Results
3. Tianyin Pharmaceutical Co., Inc. to Host First Quarter of Fiscal Year 2011 Earnings Conference Call on Thursday, November 11, 2010 at 9:00 a.m. ET
4. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2010 Earnings Conference Call on Thursday, September 30, 2010 at 9:00 a.m. ET
5. Tianyin Corporate Presentation Updated
6. Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6
7. Tianyin Promotes its Flagship Product Portfolio at the 45th 2010 National New Special Drugs Trade Fair in July at Beijing
8. Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET
9. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
10. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... , March 28, 2017  CASI Pharmaceuticals, ... innovative therapeutics addressing cancer and other unmet medical ... American Association for Cancer Research annual meeting.  The ... is entitled "Evaluation of ENMD-2076 in Combination ... the second poster to be presented on April ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... ... 2017 , ... Qualidigm , the mission-driven national healthcare ... new, more expansive office space in order to accommodate its growing number of ... building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately began ...
Breaking Medicine News(10 mins):